

Atty. Docket No.: PG3416US2

contd.
q1

8. (Amended) A method as claimed in claim 3, wherein the susceptible cancer is a susceptible pancreatic cancer.

9. (Amended) A method as claimed in claim 3, wherein the susceptible cancer is a susceptible head and neck cancer.

Sub
B1

10. (Amended) A method as claimed in claim 3, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR.


11. (Amended) A method as claimed in claim 3, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of erbB-2.

12. (Amended) A method as claimed in claim 3, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR and erbB-2.

Please add claims 13-19.

q2

-13. (New) A compound of the formula:



and salts or solvates thereof.

14. (New) A pharmaceutical formulation, comprising: the compound of claim 13 or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Atty. Docket No.: PG3416US2

contd.
a2
Sub
B1

15. (New) A method of treating a susceptible cancer in a human or animal subject mammal, comprising administering to said subject an effective amount of a compound as claimed in claim 13.

16. (New) A method as claimed in claim 16, wherein the susceptible cancer is a susceptible breast cancer.

17. (New) A method as claimed in claim 16, wherein the susceptible cancer is a susceptible non-small cell lung cancer. B

18. (New) A method as claimed in claim 16, wherein the susceptible cancer is a susceptible ovarian cancer.

Sub
B1

19. (New) A method as claimed in claim 16, wherein the susceptible cancer is a susceptible stomach cancer.

20. (New) A method as claimed in claim 16, wherein the susceptible cancer is a susceptible pancreatic cancer. B

21. (New) A method as claimed in claim 16, wherein the susceptible cancer is a susceptible head and neck cancer.

Sub
B1

22. (New) A method as claimed in claim 16, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR.

23. (New) A method as claimed in claim 16, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of erbB-2.


24. (New) A method as claimed in claim 16, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR and erbB-2.

Atty. Docket No.: PG3416US2

contd.
a/2

Sub
B1

25. (New) A compound of the formula:



and salts or solvates thereof.

26. (New) A pharmaceutical formulation, comprising: the compound of claim 25 or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers, diluents, or excipients.

27. (New) A method of treating a susceptible cancer in a human or animal subject mammal, comprising administering to said subject an effective amount of a compound as claimed in claim 25.

28. (New) A method as claimed in claim 27, wherein the susceptible cancer is a susceptible breast cancer.

29. (New) A method as claimed in claim 27, wherein the susceptible cancer is a susceptible non-small cell lung cancer. *B*

30. (New) A method as claimed in claim 27, wherein the susceptible cancer is a susceptible ovarian cancer.

Sub
B1

31. (New) A method as claimed in claim 27, wherein the susceptible cancer is a susceptible stomach cancer.

32. (New) A method as claimed in claim 27, wherein the susceptible cancer is a susceptible pancreatic cancer. *B*

Atty. Docket No.: PG3416US2

*contd.
p 2*

*Sub
p 1*

33. (New) A method as claimed in claim 27, wherein the susceptible cancer is a susceptible head and neck cancer.

34. (New) A method as claimed in claim 27, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR.

35. (New) A method as claimed in claim 27, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of erbB-2.

36. (New) A method as claimed in claim 27, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR and erbB-2.